


Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{array}{lll} \textbf{Product Name} & : MYLS22 \\ \textbf{Cat.No.} & : URK-V2320 \\ \textbf{CAS No.} & : 306959-01-3 \\ \textbf{Molecular Formula} & : C_{24}H_{21}N_5O_2S \\ \textbf{Molecular Weight} & : 443.52 \\ \end{array}$

Target : Solubility :



Biological Activity

MYLS22 is a specific, nontoxic small molecule inhibitor of the inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1), curtails tumor growth and metastasisin vitro and in vivo.

MYLS22 downregulates the angiogenic factors (FGFR, FGF, EGF, and PDGF) used by tumors escaping from VEGF inhibitors.

MYLS22 (peritumoral injection 10 mg/kg/die) curtailed tumor growth, did not display any additive effect in Opa1+/ Δ EC mice.

Pharmacological OPA1 inhibition via MYLS22 reduces breast cancer hallmarks in vitro.

References

- 1. Herkenne S, et al. Cell Metab. 2020 May 5;31(5):987-1003.e8.
- 2. Corrado M, et al. Cell Death Differ. 2021 Jul;28(7):2194-2206.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!